Abstract

SummaryPhenotypic screening identified a benzothiophene compound with activity against Leishmania donovani, the causative agent of visceral leishmaniasis. Using multiple orthogonal approaches, oxidosqualene cyclase (OSC), a key enzyme of sterol biosynthesis, was identified as the target of this racemic compound and its enantiomers. Whole genome sequencing and screening of a genome-wide overexpression library confirmed that OSC gene amplification is associated with resistance to compound 1. Introduction of an ectopic copy of the OSC gene into wild-type cells reduced susceptibility to these compounds confirming the role of this enzyme in resistance. Biochemical analyses demonstrated the accumulation of the substrate of OSC and depletion of its product in compound (S)-1-treated-promastigotes and cell-free membrane preparations, respectively. Thermal proteome profiling confirmed that compound (S)-1 binds directly to OSC. Finally, modeling and docking studies identified key interactions between compound (S)-1 and the LdOSC active site. Strategies to improve the potency for this promising anti-leishmanial are proposed.

Highlights

  • The protozoan parasites Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp. are the causative agents of the vector-borne diseases African sleeping sickness, Chagas disease, and the leishmaniases

  • Alongside robust surveillance screening programs and vector control measures, has significantly reduced cases of African sleeping sickness, raising hopes that this disease may be eliminated as a public health problem in the near future (Barrett, 2018)

  • Our studies focused on using multiple unbiased approaches to determine the mechanism(s) of action (MoA) of this compound in L. donovani

Read more

Summary

Introduction

The protozoan parasites Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp. are the causative agents of the vector-borne diseases African sleeping sickness, Chagas disease, and the leishmaniases. These diseases are responsible for more than 50,000 fatalities annually and the loss of more than 4,600,000 disease-adjusted life years (www.who.int/leishmaniasis/burden). New drugs for Chagas disease and leishmaniasis have been more difficult to develop. New drugs that are safer, efficacious, and suitable for use in resource-poor settings are urgently required for the treatment of these neglected tropical diseases

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.